Eli Lilly’s Oscars commercial slams unapproved drugs like compounded GLP-1s: The ad could help pharma companies rebuild trust with consumers.
Medical misinformation ‘infodemic’ on social media: Influencers are promoting misleading information about medical tests. Here’s what healthcare and pharma brands should be doing to combat it.
Microsoft, Google enhance genAI offerings for clinicians: We examine the race between startups, health tech companies, and Big Tech giants to show healthcare organizations how their AI tools will drive efficiency-–and why Microsoft could have a leg up on the competition.
What Gen Z wants from pharma: We present the data on how Gen Z feels about pharma communications and explore how marketers can more effectively reach younger consumers.
Healthcare stakeholders push Congress to make Medicare coverage of telehealth permanent: It’s set to expire at the end of March. We explore what’s at stake for seniors, many of whom are used to getting care remotely.
Placing Aria Gen 2 in research labs could help Meta gather real-world data—turning researchers into de facto product testers for its next wave of consumer smart glasses.
Doctors should ask their patients to write online reviews—and then respond to feedback: It will go a long way in attracting and retaining patients.
Trump issues executive order to make healthcare prices more transparent: Price rules finalized during his first term haven’t had an impact. Could it be different this time around?
Talks of a Walgreens take-private sale are ramping up again: Walgreens could be divided into three parts if the sale proceeds. We explore the likelihood of a deal going through and what it means for Walgreens’ future.
Only 18% of consumers have ever asked their doctor about a drug ad: But when they do, many patients walk away with a prescription for that medication. We explore how pharma marketers can get the most out of their ad campaigns.
Hims & Hers will still sell compounded semaglutide to some patients: The company isn’t ready to admit defeat in the battle between compounded GLP-1 sellers and Big Pharma. But Hims’ competitive advantage in the weight loss drug market is getting weaker.
US docs spend up to 3 hours per week correcting AI: Physicians’ liability concerns with AI can be addressed by having them involved with technology purchasing decisions.
DOJ will examine UnitedHealth’s Medicare billing practices: The Trump administration has made “waste, fraud, and abuse” a rallying cry. Now, we find out how serious they are about it.
The Ozempic shortage is over: We explore how an FDA decision impacts compounded weight loss drug sellers like Hims & Hers and patients who are prescribed GLP-1s.
HHS instructs CDC to shelve vaccine ads, including for the flu: RFK Jr. was at the helm of a decision to halt the CDC’s vaccine-focused advertisements—an early indicator of the steps he’s willing to take in his new role as HHS Secretary.
Hims & Hers moves into at-home testing: Its recent acquisition of a small lab testing company could have a big payoff.
“Dr. AI” is the new “Dr. Google”: 60% of US consumers have used AI for health guidance. Healthcare marketers and providers should educate the public on responsible use of AI for medical purposes.
Talkspace posts its first full year of profitability: But it’s not all rosy. It’s catching heat for sending teens’ data to social media platforms. Talkspace must be sure not to spoil its prosperity by damaging its reputation.
News and magazine apps have the highest engagement score in North America, with 29% of monthly active users coming back daily, according to a September 2024 Airship survey.
RFK to lead Trump’s Make America Healthy Again commission: Trump’s executive order outlines policies and actions that could impact medication access for children, how quickly drugs get to market, and how federal health agencies conduct research.